))
Episode 62: Josh Mandel-Brehm - CEO, CAMP4 Therapeutics
Manage episode 418244435 series 3526490
Innehåll tillhandahållet av Vial. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Vial eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Explore the untapped potential of RNA amplifying therapeutics with the CEO of CAMP4 Therapeutics, Josh Mandel-Brehm. We uncover the power of antisense oligonucleotides in rewriting the narrative for genetic diseases characterized by protein deficiency. Josh takes us behind the scenes of their innovative RNA Actuating Platform (RAP), a map charting the course of gene expression and a guide to the regulatory RNAs that can turn up the volume on genes gone silent due to disease. It's a pioneering journey through the promising avenues of metabolic disease treatment, with a special spotlight on their developmental star, CMP-CPS-001.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. View the full transcript here.
Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
Kapitel
1. Episode 62: Josh Mandel-Brehm - CEO, CAMP4 Therapeutics (00:00:00)
2. Revolutionizing Treatments With RNA Therapeutics (00:00:06)
3. Exploring Dark Genome for Therapeutic Advances (00:11:31)
4. Partnerships for Drug Development Vision (00:19:10)
62 episoder
Dela
